Amica Retiree Medical Trust Sells 28 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Amica Retiree Medical Trust lessened its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 7.9% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 327 shares of the biopharmaceutical company’s stock after selling 28 shares during the quarter. Amica Retiree Medical Trust’s holdings in Regeneron Pharmaceuticals were worth $233,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of REGN. Great Valley Advisor Group Inc. lifted its position in Regeneron Pharmaceuticals by 5.0% in the 3rd quarter. Great Valley Advisor Group Inc. now owns 442 shares of the biopharmaceutical company’s stock valued at $465,000 after acquiring an additional 21 shares in the last quarter. Kingsview Wealth Management LLC raised its stake in shares of Regeneron Pharmaceuticals by 2.6% in the third quarter. Kingsview Wealth Management LLC now owns 860 shares of the biopharmaceutical company’s stock worth $904,000 after purchasing an additional 22 shares during the last quarter. Larson Financial Group LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 127.3% in the third quarter. Larson Financial Group LLC now owns 50 shares of the biopharmaceutical company’s stock valued at $53,000 after purchasing an additional 28 shares in the last quarter. Independent Advisor Alliance purchased a new position in shares of Regeneron Pharmaceuticals during the third quarter valued at approximately $231,000. Finally, Truvestments Capital LLC bought a new stake in Regeneron Pharmaceuticals during the third quarter worth $39,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Up 0.9 %

Shares of NASDAQ REGN opened at $640.14 on Thursday. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09. The company has a market cap of $69.98 billion, a P/E ratio of 16.72, a P/E/G ratio of 2.34 and a beta of 0.27. Regeneron Pharmaceuticals, Inc. has a 52 week low of $629.02 and a 52 week high of $1,211.20. The business has a 50-day simple moving average of $685.91 and a two-hundred day simple moving average of $805.04.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, beating analysts’ consensus estimates of $11.21 by $0.86. The company had revenue of $3.79 billion during the quarter, compared to analyst estimates of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. Regeneron Pharmaceuticals’s revenue was up 10.3% compared to the same quarter last year. During the same period last year, the business earned $11.86 earnings per share. Research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th were issued a $0.88 dividend. The ex-dividend date was Thursday, February 20th. This represents a $3.52 annualized dividend and a dividend yield of 0.55%. Regeneron Pharmaceuticals’s payout ratio is currently 2.30%.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the stock. Bank of America reaffirmed an “underperform” rating and set a $565.00 price objective on shares of Regeneron Pharmaceuticals in a report on Tuesday, December 10th. Leerink Partnrs upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Wednesday, February 5th. Bernstein Bank reduced their price objective on shares of Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research report on Tuesday, February 4th. TD Cowen dropped their target price on shares of Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a “buy” rating on the stock in a research report on Tuesday, February 4th. Finally, Wells Fargo & Company cut their target price on Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating on the stock in a research note on Friday, January 10th. One analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have issued a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $973.13.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.